- Brunet-Ratnasingham, Elsa;
- Morin, Sacha;
- Randolph, Haley;
- Labrecque, Marjorie;
- Bélair, Justin;
- Lima-Barbosa, Raphaël;
- Pagliuzza, Amélie;
- Marchitto, Lorie;
- Hultström, Michael;
- Niessl, Julia;
- Cloutier, Rose;
- Sreng Flores, Alina;
- Brassard, Nathalie;
- Benlarbi, Mehdi;
- Prévost, Jérémie;
- Ding, Shilei;
- Anand, Sai;
- Sannier, Gérémy;
- Marks, Amanda;
- Wågsäter, Dick;
- Bareke, Eric;
- Zeberg, Hugo;
- Lipcsey, Miklos;
- Frithiof, Robert;
- Larsson, Anders;
- Zhou, Sirui;
- Nakanishi, Tomoko;
- Morrison, David;
- Vezina, Dani;
- Bourassa, Catherine;
- Gendron-Lepage, Gabrielle;
- Medjahed, Halima;
- Point, Floriane;
- Richard, Jonathan;
- Larochelle, Catherine;
- Prat, Alexandre;
- Cunningham, Janet;
- Arbour, Nathalie;
- Durand, Madeleine;
- Richards, J;
- Moon, Kevin;
- Chomont, Nicolas;
- Finzi, Andrés;
- Tétreault, Martine;
- Barreiro, Luis;
- Wolf, Guy;
- Kaufmann, Daniel
Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients with COVID-19. Integrated analysis using k-means reveals four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors segregate into high and low early antibody responders. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4+ T cell frequencies. These data suggest that the Interferon paradox previously described in murine LCMV models is operative in COVID-19, with excessive IFN signaling delaying development of adaptive virus-specific immunity.